In response to escalating cases of serogroup W (MenW) invasive meningococcal disease (IMD), multiple countries introduced quadrivalent conjugate MenACWY vaccines into their national immunization programs (NIPs). Here, we summarize the real-world impact and vaccine effectiveness (VE) data of MenACWY-TT from Chile, England, the Netherlands, and Australia. Incidence rate reductions (IRRs) and VE from baseline to post-NIP period were extracted from publications or calculated. After the administration of a single dose of MenACWY-TT, substantial IRRs of MenCWY were observed across the countries in vaccine-eligible age groups (83%-85%) and via indirect protection in non-vaccine-eligible age groups (45%-53%). The impact of MenACWY-TT was primarily driven by MenW IRRs, as seen in vaccine-eligible age groups (65%-92%) and non-vaccine-eligible age groups (41%-57%). VE against MenW was reported in vaccine-eligible toddlers (92%) in the Netherlands and in vaccine-eligible adolescents/young adults (94%) in England. These real-world data support the implementation and continued use of MenACWY-TT in NIPs.

Centre for Epidemiology and Microbiology National Institute of Public Health Prague Czech Republic

Department of Pediatrics Faculty of Medicine Universidad de Chile Santiago Chile

Infectious Diseases Unit Hospital de niños Dr Exequiel González Cortés Santiago Chile

Vaccine Medical Development and Scientific Clinical Affairs Pfizer Inc Collegeville PA USA

Vaccine Medical Development and Scientific Clinical Affairs Pfizer Inc Paris France

Vaccine Medical Development and Scientific Clinical Affairs Pfizer Ltd Tadworth UK

Zobrazit více v PubMed

Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. doi:10.1186/1478-7954-11-17. PubMed DOI PMC

Harrison LH, Trotter CL, Ramsay ME.. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–8. doi:10.1016/j.vaccine.2009.04.063. PubMed DOI

Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30(Suppl 2):B10–7. doi:10.1016/j.vaccine.2011.12.060. PubMed DOI

WHO . WHO vaccine-preventable diseases: monitoring system. 2020 global summary. [accessed 2022 Jan 27]. https://apps.who.int/immunization_monitoring/globalsummary/schedules.

Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJM, Pollard AJ, Turner DPJ, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–31. doi:10.1016/S0140-6736(14)60842-4. PubMed DOI

Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, et al. The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15–30. doi:10.1080/14760584.2019.1557520. PubMed DOI

Ohm M, Hahne SJM, van der Ende A, Sanders EAM, Berbers GAM, Ruijs WLM, van Sorge NM, de Melker HE, Knol MJ. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis. 2022;74(12):2173–80. doi:10.1093/cid/ciab791. PubMed DOI PMC

Carr JP, MacLennan JM, Plested E, Bratcher HB, Harrison OB, Aley PK, Bray JE, Camara S, Rodrigues CMC, Davis K, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28(12):1649 e1–e8 . doi:10.1016/j.cmi.2022.07.004. PubMed DOI

Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23(17–18):2222–7. doi:10.1016/j.vaccine.2005.01.051. PubMed DOI

Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851–61. doi:10.1586/erv.09.48. PubMed DOI PMC

Andrade AL, Minamisava R, Tomich LM, Lemos AP, Gorla MC, de Cunto Brandileone MC, Domingues CMS, de Moraes C, Policena G, Bierrenbach AL, et al. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. Vaccine. 2017;35(16):2025–33. doi:10.1016/j.vaccine.2017.03.010. PubMed DOI

Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Préziosi M-P, Stuart JM. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis. 2017;17(8):867–72. doi:10.1016/S1473-3099(17)30301-8. PubMed DOI

Bwaka A, Bita A, Lingani C, Fernandez K, Durupt A, Mwenda JM, Mihigo R, Djingarey MH, Ronveaux O, Preziosi M-P, et al. Status of the rollout of the meningococcal serogroup a conjugate vaccine in African meningitis belt countries in 2018. J Infect Dis. 2019;220(Supplement_4):S140–S7. doi:10.1093/infdis/jiz336. PubMed DOI PMC

Krone M, Gray S, Abad R, Skoczynska A, Stefanelli P, van der Ende A, Tzanakaki G, Mölling P, João Simões M, Křížová P, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24(14):24. doi:10.2807/1560-7917.ES.2019.24.14.1800245. PubMed DOI PMC

Whittaker R, Dias JG, Ramliden M, Kodmon C, Economopoulou A, Beer N, Pastore Celentano L, Kanitz E, Richter L, Mattheus W, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine. 2017;35(16):2034–41. doi:10.1016/j.vaccine.2017.03.007. PubMed DOI

Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–98. doi:10.1016/j.jinf.2020.05.079. PubMed DOI

Nimenrix (meningococcal group A, C, W-135 and Y conjugate vaccine). Summary of Product Characteristics, Pfizer Manufacturing Belgium N.V., Belgium; 2017.

Mbaeyi S, Pondo T, Blain A, Yankey D, Potts C, Cohn A, Hariri S, Shang N, MacNeil JR. Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. JAMA Pediatr. 2020;174(9):843–51. doi:10.1001/jamapediatrics.2020.1990. PubMed DOI PMC

Villena R, Valenzuela MT, Bastias M, Santolaya ME. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction. Vaccine. 2022;40(4):666–72. doi:10.1016/j.vaccine.2021.11.075. PubMed DOI

Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME, Ladhani SN, et al. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022;6(2):96–105. doi:10.1016/S2352-4642(21)00335-7. PubMed DOI

Public Health England . Vaccine coverage estimates for the meningococcal ACWY (MenACWY) adolescent vaccination programme in schools across England, in 2018/19; and for the GP-based catch-up programme, to end of August 2019. [accessed 2022 Jan 27]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/953825/hpr0220_menACWY-vc.pdf.

Lahra MM, Hogan TR, National Neisseria Network A . Australian meningococcal surveillance programme annual report, 2019. Commun Dis Intell (2018). 2020;44. doi:10.33321/cdi.2020.44.10. PubMed DOI

Sharma K, Chiu C, Wood N. Meningococcal vaccines in Australia: a 2019 update. Aust Prescr. 2019;42(4):131–5. doi:10.18773/austprescr.2019.042. PubMed DOI PMC

National center for immunisation research and surveillance Australia. Annual immunisation coverage report; 2020. [accessed 2022 Jul 27]. https://www.ncirs.org.au/sites/default/files/2022-07/NCIRS%20Annual%20Immunisation%20Coverage%20Report%202020.pdf.

Lahra MM, Enriquez RP, George CRR. Australian meningococcal surveillance programme annual report, 2017. Commun Dis Intell (2018). 2019;43. doi:10.33321/cdi.2019.43.66. PubMed DOI

Villena R, Valenzuela MT, Bastias M, Santolaya ME. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine. 2019;37(46):6915–21. doi:10.1016/j.vaccine.2019.09.050. PubMed DOI

Australian Bureau of Statistics . [accessed 2022 Mar 2]. https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2020.

United Nations Development Progamme . [accessed 2022 Mar 2]. http://hdr.undp.org/en/indicators/44206.

Serra L, Knuf M, Martinon-Torres F, Yi K, Findlow J. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines. Hum Vaccin Immunother. 2021;17(7):2205–15. doi:10.1080/21645515.2020.1855952. PubMed DOI PMC

Vaccine schedules in all countries in the EU/EEA. [accessed 2022 Feb 9]. https://vaccine-schedule.ecdc.europa.eu/.

Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, Ladhani S. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015–2016. Emerg Infect Dis. 2017;23(7):1184–7. doi:10.3201/eid2307.170236. PubMed DOI PMC

National Health Service MenACWY Vaccine . [accessed 2022 Jun 22]. https://www.nhs.uk/conditions/vaccinations/men-acwy-vaccine/.

Erlich KS, Congeni BL. Importance of circulating antibodies in protection against meningococcal disease. Hum Vaccin Immunother. 2012;8(8):1029–35. doi:10.4161/hv.20473. PubMed DOI PMC

Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau D, Miller J. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013;13(1):116. doi:10.1186/1471-2334-13-116. PubMed DOI PMC

Klein NP, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M. Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children. Pediatr Infect Dis J. 2016;35(6):662–72. doi:10.1097/INF.0000000000001123. PubMed DOI

Knuf M, Helm K, Kolhe D, Van Der Wielen M, Baine Y. Antibody persistence and booster response 68 months after vaccination at 2–10 years of age with one dose of MenACWY-TT conjugate vaccine. Vaccine. 2018;36(23):3286–95. doi:10.1016/j.vaccine.2018.04.064. PubMed DOI

Quiambao BP, Bavdekar A, Dubey AP, Jain H, Kolhe D, Bianco V, Miller JM, Van der Wielen M. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents. Hum Vaccin Immunother. 2017;13(3):636–44. doi:10.1080/21645515.2016.1248009. PubMed DOI PMC

Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother. 2016;12(1):132–9. doi:10.1080/21645515.2015.1058457. PubMed DOI PMC

Vesikari T, Forsten A, Laudat F, Li P, Van Der Wielen M, Hezareh M, Perez JL, Webber C. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children. Vaccine. 2020;38(22):3902–8. doi:10.1016/j.vaccine.2020.02.030. PubMed DOI

Clark SA, Borrow R. Herd protection against meningococcal disease through vaccination. Microorganisms. 2020;8(11). doi:10.3390/microorganisms8111675. PubMed DOI PMC

Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286(6):688–93. doi:10.1001/jama.286.6.688. PubMed DOI

Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–43. doi:10.1086/527401. PubMed DOI PMC

Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbe M, Toralta J, Kodbesse B, Ngadoua C, Coldiron ME, et al. Effect of a serogroup a meningococcal conjugate vaccine (PsA–TT) on serogroup a meningococcal meningitis and carriage in Chad: a community study. Lancet. 2014;383(9911):40–7. doi:10.1016/S0140-6736(13)61612-8. PubMed DOI PMC

Delbos V, Lemee L, Benichou J, Berthelot G, Deghmane AE, Leroy JP, Houivet E, Hong E, Taha M-K, Caron F, et al. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine. 2013;31(40):4416–20. doi:10.1016/j.vaccine.2013.06.080. PubMed DOI

Oldfield NJ, Green LR, Parkhill J, Bayliss CD, Turner DPJ. Limited impact of adolescent meningococcal ACWY vaccination on Neisseria meningitidis serogroup W carriage in university students. J Infect Dis. 2018;217(4):608–16. doi:10.1093/infdis/jix596. PubMed DOI PMC

Chang Q, Tzeng YL, Stephens DS. Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol. 2012;4:237–45. doi:10.2147/CLEP.S28410. PubMed DOI PMC

Informe Regional SIREVA 2017 . Argentina Información sobre la vigilancia de las neumonías y meningitis bacterianas. SIREVA II. OPS. 2019 Neisseria meningitidis. http://antimicrobianos.com.ar/ATB/wp-content/uploads/2021/01/Meningo-2019.pdf.

Grundy EM, Albala C, Allen E, Dangour AD, Elbourne D, Uauy R. Grandparenting and psychosocial health among older Chileans: a longitudinal analysis. Aging Ment Health. 2012;16(8):1047–57. doi:10.1080/13607863.2012.692766. PubMed DOI PMC